long-term delivery of protein therapeutics蛋白质疗法的长期交付.pdfVIP

HHS Public Access Author manuscript A Expert Opin Drug Deliv . Author manuscript; available in PMC 2015 October 14. u t h Published in final edited form as: o r Expert Opin Drug Deliv . 2015 March ; 12(3): 415–440. doi:10.15172015.961420. M a n u s c Long-Term Delivery of Protein Therapeutics r i p t Ravi Vaishya, University of Missouri-Kansas City, Pharmaceutical Sciences, United States, vrdd54@mail.umkc.edu Dr Varun Khurana, INSYS Therapeutics Inc, United States; University of Missouri-Kansas City, Pharmaceutical A u Sciences, United States, varunkhurana@mail.umkc.edu t h o Dr Sulabh Patel, and r M University of Missouri-Kansas City, Pharmaceutical Sciences, United States, a n spp2m9@mail.umkc.edu u s c Professor Ashim K Mitra r i p University of Missouri-Kansas City, Pharmaceutical Sciences, kansas city, United Kingdom t Abstract Introduction—Proteins are effective biotherapetics with applications in diverse ailments. Despite being specific and potent, their full clinical potential has not yet been realized. This can be attributed to short half-lives, complex structures, poor in vivo stability, low permeability frequent A u parenteral administrations and poor adherence to treatment in chronic diseases. A sustained release t h o system, providing controlled release of proteins, may overcome many of these limitations. r M Areas covered—This review focuses on recent development in approaches, especially polymer- a n based formulations, which can provide therapeutic levels of prot